Recombinant Human Cation-dependent mannose-6-phosphate receptor (M6PR)-VLPs

What is the structural difference between cation-dependent (CD-MPR) and cation-independent (CI-MPR) mannose-6-phosphate receptors?

The cation-dependent mannose 6-phosphate receptor (CD-MPR) is a 46-kDa type I membrane glycoprotein that exists as a homodimer, with each subunit containing a single mannose 6-phosphate (Man-6-P) binding site . In contrast, the cation-independent mannose 6-phosphate receptor (CI-MPR) is a much larger 300-kDa protein with multiple Man-6-P binding sites that map to domains 3, 5, and 9 within its 15-domain extracytoplasmic region .

The CD-MPR shows a 4-fold increase in binding affinity toward Man-6-P and lysosomal enzymes in the presence of divalent cations, though unlike C-type lectins, it does not have an absolute requirement for calcium . The CI-MPR's three Man-6-P binding sites have distinct properties, with domain 9 binding lysosomal enzymes with high affinity when expressed alone, while domain 3 requires the presence of domains 1 and 2 to form a high-affinity carbohydrate binding site .

How does pH affect the binding capabilities of M6PR, and what implications does this have for VLP design?

The interaction between MPRs and their ligands is highly pH-dependent. The CD-MPR binds lysosomal enzymes optimally in the pH environment of the trans Golgi network (pH ~6.5) and releases its cargo in acidic endosomal compartments (<pH 5.5) and at the cell surface . Crystallographic studies have shown that the CD-MPR bound to Man-6-P at pH 6.5 adopts a significantly different quaternary conformation than the CD-MPR in a ligand-unbound state .

When designing M6PR-VLPs, researchers must consider this pH dependency, as it will affect the binding and release properties of the construct. For applications requiring cargo binding in neutral environments and release in acidic conditions (such as endosomal drug delivery), the natural pH sensitivity of M6PR can be advantageous. Conversely, for applications requiring stable binding across pH ranges, protein engineering approaches may be necessary to modify the pH dependency.

What molecular mechanisms underlie the pH-dependent ligand binding of M6PR?

The pH-dependent binding of the CD-MPR to its ligands involves several molecular mechanisms:

• At pH 6.4 (optimal for ligand binding), the phosphate group of Man-6-P exists in nearly equivalent populations of singly and doubly deprotonated species (pK₂ for the acid dissociation of the phosphate moiety of Man-6-P is approximately 6.4) .

• His-105 appears to play a key role in modulating ligand interactions, as it is the only residue of the receptor with a titratable side chain (typical pKₐ of histidine is ~6.0-6.5) involved in binding the phosphate moiety of Man-6-P .

• Structural studies show that at pH 4.8, the binding site of the CD-MPR adopts a closed conformation that is incompatible with ligand binding, while at pH 6.5 with Man-6-P bound, the receptor adopts an open conformation that accommodates the ligand .

• Divalent cations, particularly Mn²⁺, coordinate with one of the carboxylate oxygens of Asp-103, the most solvent-accessible oxygen of the phosphate group of Man-6-P, and four water molecules at pH 6.5, enhancing binding affinity .

What expression systems are most effective for producing functional recombinant M6PR constructs?

Based on the literature, several expression systems have been successfully used for producing functional recombinant M6PR constructs:

• Pichia pastoris expression system: The pGAPZαA expression vector (Invitrogen) has been effectively used for expressing truncated forms of the CI-MPR, including domain constructs Dom1-3, Dom7-11, Dom5His, and Dom9His . This system is particularly advantageous for expressing proteins that require post-translational modifications, including glycosylation.

• Mammalian cell expression: For studies requiring native-like glycosylation patterns, mammalian expression systems are often preferred. MTX 3.2 cells have been used to express and purify human β-glucuronidase, which can be subsequently purified using CI-MPR affinity chromatography .

When designing expression constructs, researchers should consider whether to include His-tags for purification purposes, as has been done with Dom1-3His, Dom5His, and Dom9His constructs . Additionally, site-directed mutagenesis may be used to eliminate N-glycosylation sites that might interfere with protein functionality, as demonstrated with the Dom5His construct where Asn at position 711 was replaced with Gln .

What methodologies can be employed to characterize the binding specificity of different M6PR domains?

Several methodologies have proven effective for characterizing binding specificity of M6PR domains:

• Surface Plasmon Resonance (SPR): Quantitative SPR analyses using modified lysosomal enzymes (e.g., acid α-glucosidase, GAA) with specific phosphorylation patterns can determine binding kinetics and affinities for different M6PR domains .

• In vitro phosphorylation and modification: Recombinant enzymes such as GlcNAc phosphotransferase can be used to generate specifically phosphorylated glycans for binding studies. These can be further modified using uncovering enzyme and/or sweet potato purple acid phosphatase to generate lysosomal enzymes highly enriched in either phosphomonoesters or phosphodiesters .

• Crystallographic studies: X-ray crystallography of M6PR domains in complex with various ligands provides detailed structural information about binding interactions. Crystals obtained at different pH values (e.g., pH 6.5, 4.8, 7.4) can reveal conformational changes that affect ligand binding .

• Glycan array technologies: Fluorescently labeled glycans (e.g., with 2-amino-N-(2-aminoethyl)-benzamide or AEAB) can be separated by HPLC and analyzed by MALDI-TOF to identify binding preferences .

How can researchers generate and purify phosphorylated glycans for M6PR binding studies?

A methodical approach to generating phosphorylated glycans includes:

• Obtain N-linked oligosaccharides by peptide N-glycosidase F digestion of glycoproteins such as bovine RNase B and soybean agglutinin .

• Label the resulting mixture of reducing glycans at their reducing ends with a bifunctional fluorescent linker like 2-amino-N-(2-aminoethyl)-benzamide (AEAB) via direct conjugation through reductive amination .

• Separate the glycan-AEABs according to their size to obtain distinct fractions (e.g., Man5-Man9) .

• Incubate each fraction separately with recombinant GlcNAc phosphotransferase to phosphorylate the glycans .

• Purify the resulting phosphorylated glycans by HPLC on a porous graphatized carbon column eluted with an acetonitrile gradient (15-35%) .

• Analyze by MALDI-TOF and identify by the masses of their molecular ions .

• For generating phosphomonoesters, hydrolyze aliquots of the phosphodiester glycans with HCl (0.01 M HCl, 1 h at 100°C) to remove the GlcNAc .

What types of phosphorylated glycans show highest affinity for M6PR, and how does this inform VLP design?

The CD-MPR shows preference for α1,2-linked phosphomannosyl residues over α1,3 or α1,6 linkages. Previous inhibition studies demonstrated that phosphorylated dimannosides containing α1,2 linkages were 5-8-fold more potent inhibitors of lysosomal enzyme binding compared to those containing α1,3 or α1,6 linkages, which were no better than the monosaccharide Man-6-P alone .

This preference for α1,2 linkages is particularly relevant as three of the five possible sites of phosphorylation on N-linked oligosaccharides in endogenous lysosomal enzymes contain Man-6-P groups in α1,2 linkages .

Crystal structure analysis of the CD-MPR complexed with α1,2-linked phosphorylated trimannoside (P-Man(α1,2)Man(α1,2)Man-O-(CH₂)₈COOMe) revealed that the penultimate mannose ring rotates approximately 90° relative to the corresponding ring in α1,3-linked oligosaccharides .

For VLP design, incorporating recognition elements that preferentially bind α1,2-linked phosphomannosyl residues would likely enhance targeting specificity and binding affinity to natural lysosomal enzymes.

How do the three Man-6-P binding sites of CI-MPR differ in their carbohydrate recognition specificity?

The three Man-6-P binding sites of CI-MPR (domains 3, 5, and 9) exhibit distinct carbohydrate recognition properties:

• Domain 9: When expressed alone, domain 9 binds lysosomal enzymes with high affinity . This suggests it has an intrinsically well-formed binding pocket that independently recognizes Man-6-P-containing ligands.

• Domain 3: Unlike domain 9, domain 3 requires the presence of domains 1 and 2 to form a high-affinity carbohydrate binding site . Crystal structure analysis of domains 1-3 reveals that residues in domains 1 and 2 do not directly contact Man-6-P but instead provide stabilizing interactions to the loops of the binding pocket housed within domain 3 .

• Domain 5: The binding characteristics of domain 5 appear to be influenced by adjacent domains, though the specific details of these interactions are less well characterized than those of domains 3 and 9 .

These differences in binding site characteristics allow the CI-MPR to recognize a wide range of phosphorylated N-glycan structures, which vary in type (high mannose or hybrid), size, presence of Man-6-P phosphomonoester or Man-P-GlcNAc phosphodiester residues, number of phosphorylated mannose residues, and location of phosphomannosyl residues on different branches of the N-glycan .

What role do divalent cations play in M6PR functionality, and how should this influence experimental design?

Divalent cations, particularly Mn²⁺, play a significant but not essential role in M6PR functionality:

• For CD-MPR, the presence of cations increases binding affinity toward Man-6-P and lysosomal enzymes approximately 4-fold, unlike C-type lectins that have an absolute requirement for calcium .

• Structural studies show that at pH 6.5, Mn²⁺ is present in the binding pocket of CD-MPR and is coordinated to one of the carboxylate oxygens of Asp-103, the most solvent-accessible oxygen of the phosphate group of Man-6-P, and four water molecules .

• Comparison of CD-MPR structures complexed to ligand at pH 6.5 in the presence or absence of Mn²⁺ shows no significant difference in the monomer fold (r.m.s. deviation < 0.2Å), suggesting that the cation primarily enhances binding affinity rather than altering receptor conformation .

For experimental design:

• Include 10mM MnCl₂ in binding buffer formulations when maximal affinity is desired

• Consider cation-free conditions when studying the intrinsic binding properties of the receptor

• When comparing binding data across different studies, carefully account for the presence or absence of divalent cations

How might M6PR-VLPs be utilized in targeting lysosomal storage disorders?

M6PR-VLPs offer several promising approaches for targeting lysosomal storage disorders:

• Enzyme Replacement Therapy (ERT) Enhancement: M6PR-VLPs could be designed to encapsulate or display recombinant lysosomal enzymes like acid α-glucosidase (GAA) . By mimicking the natural targeting system, these VLPs could potentially improve delivery efficiency to lysosomes compared to conventional ERT approaches.

• Cell-Specific Targeting: By engineering VLPs with CD-MPR or specific domains of CI-MPR that show optimal binding at physiological pH , researchers could develop delivery systems that selectively target cells expressing high levels of Man-6-P-modified proteins.

• pH-Responsive Drug Release: The natural pH dependency of M6PR (optimal binding at pH ~6.5, release at pH <5.5) could be exploited to create smart delivery systems that retain their cargo in circulation but release it specifically in the acidic environment of lysosomes.

• Combined Therapeutic Approaches: M6PR-VLPs could potentially carry both enzyme replacement and small molecule chaperones simultaneously, addressing multiple aspects of lysosomal storage disorders in a single therapeutic agent.

What experimental approaches can address the challenge of maintaining M6PR functionality when incorporated into VLPs?

Maintaining M6PR functionality when incorporated into VLPs presents several challenges that can be addressed through careful experimental design:

• Optimal Domain Selection: Rather than using full-length receptors, researchers should consider incorporating specific functional domains (e.g., domains 1-3 for CI-MPR, which form a complete binding unit) . The Dom1-3, Dom5His, and Dom9His constructs have been shown to maintain binding functionality and may be more amenable to VLP incorporation .

• Orientation Control: The extracytoplasmic region of M6PR must be properly oriented on the VLP surface to maintain functionality. This can be achieved through strategic design of fusion constructs that position the binding domains facing outward from the VLP surface.

• Glycosylation Management: Site-directed mutagenesis can be used to eliminate potentially interfering N-glycosylation sites while preserving functionality, as demonstrated with the Dom5His construct where Asn at position 711 was replaced with Gln .

• pH and Cation Optimization: Buffer conditions during production, purification, and storage should be carefully controlled to maintain optimal pH (~6.5) and include appropriate divalent cations (e.g., 10mM MnCl₂) to preserve binding functionality .

• Functional Verification: SPR analysis using well-characterized ligands such as specifically modified GAA (with either phosphomonoesters or phosphodiesters) can confirm that M6PR domains retain their binding specificity and affinity when incorporated into VLPs.

How can researchers quantitatively evaluate the binding kinetics of M6PR-VLPs to target molecules?

Quantitative evaluation of M6PR-VLP binding kinetics requires sophisticated methodological approaches:

• Surface Plasmon Resonance (SPR):

  • Immobilize M6PR-VLPs on sensor chips and flow target molecules (e.g., phosphorylated lysosomal enzymes) at various concentrations

  • Alternatively, immobilize target molecules and flow M6PR-VLPs

  • Analyze association and dissociation phases to determine kon and koff rates

  • Calculate equilibrium dissociation constants (KD) to quantify binding affinity

• Isothermal Titration Calorimetry (ITC):

  • Directly measure thermodynamic parameters of binding (ΔH, ΔS, ΔG)

  • Determine binding stoichiometry to understand how many ligands can bind per VLP

  • Assess binding under various pH conditions (e.g., pH 6.5, 5.5, 7.4) to characterize pH dependency

• Fluorescence-based Assays:

  • Label target molecules with fluorophores and measure binding through fluorescence polarization or FRET

  • Use competition assays with known ligands like P-Man(α1,2)Man(α1,2)Man-O-(CH₂)₈COOMe to determine relative binding affinities

• Functional Cell-based Assays:

  • Quantify uptake of fluorescently-labeled M6PR-VLPs in cell lines expressing different levels of phosphorylated targets

  • Compare uptake in the presence of inhibitors like free Man-6-P or specific antibodies against M6PR domains

  • Evaluate pH-dependent binding and release through endosomal pH manipulation

What analytical methods can be used to verify the structural integrity of M6PR domains on VLP surfaces?

Multiple analytical approaches can verify structural integrity of M6PR domains on VLP surfaces:

What are the critical parameters for optimizing pH-dependent binding and release properties of M6PR-VLPs?

To optimize pH-dependent binding and release properties of M6PR-VLPs, researchers should focus on these critical parameters:

• Histidine Residue Engineering: Since His-105 appears critical for pH-dependent binding in CD-MPR , targeted mutagenesis of this and other histidine residues can fine-tune the pH profile of binding and release. Substituting histidines with residues having different pKa values can shift the pH optimum.

• Buffer Composition Control:

  • Maintain precise pH control during production and storage (optimal pH ~6.5 for binding)

  • Include appropriate concentrations of divalent cations (e.g., 10mM MnCl₂) to enhance binding affinity

  • Consider ionic strength effects on binding stability across pH ranges

• Domain Selection and Engineering:

  • Different domains (3, 5, and 9 of CI-MPR) may have slightly different pH dependencies

  • Create chimeric constructs combining optimal pH-responsive elements from different domains

  • Introduce stabilizing interactions that preserve binding pocket geometry at non-optimal pH conditions

• Ligand Modification:

  • Engineer the phosphate groups on target molecules, considering that the pK₂ for Man-6-P is approximately 6.4

  • Modify the chemical environment around the phosphate group to alter its protonation/deprotonation behavior

• Experimental Validation:

  • Test binding and release across fine-grained pH gradients (pH 4.5-8.0 in 0.2-0.3 unit increments)

  • Use SPR to quantify binding kinetics at each pH value

  • Verify in cellular systems by measuring uptake and intracellular trafficking under varied pH conditions

By systematically addressing these parameters, researchers can develop M6PR-VLPs with customized pH-responsive properties suited to specific therapeutic or research applications.